June 20, 2020Journal of the American Academy of Dermatology399 citationsOpen Access
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial
View Full Paper
Key Points
Key points are not available for this paper at this time.
Abstract
Dupilumab + TCS is efficacious and well tolerated in children with severe AD, significantly improving signs, symptoms, and QOL.
Cite This Study
Paller et al. (2020) studied this question.